Jazz Pharmaceuticals JAZZ Excess tax benefits associated with employee equity plans
Excess tax benefits associated with employee equity plans at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans?
- Jazz Pharmaceuticals (JAZZ) reported excess tax benefits associated with employee equity plans of $1.26M in Q4 2025.
- How has Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans changed year-over-year?
- Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans decreased by 72.1% year-over-year, from $4.52M to $1.26M.
- What is the long-term trend for Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's excess tax benefits associated with employee equity plans has grown at a -2.4% compound annual growth rate (CAGR), from -$5.56M to $5.05M.
- What does excess tax benefits associated with employee equity plans mean?
- Tax savings generated from employee stock-based compensation plans.
- How do you interpret excess tax benefits associated with employee equity plans?
- An increase signals higher tax savings, often driven by higher stock price performance during vesting or exercise periods.
- How does excess tax benefits associated with employee equity plans compare across companies?
- Common in high-growth or tech-heavy sectors; highly dependent on stock price volatility and equity grant volume.